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Endophenotypes are heritable quantitative traits that are associated with disease liability, can be measured in both affected and 
unaffected individuals, and provide much greater power to localize and identify risk genes for mental illness than does affection 
status alone. Traditionally, endophenotypic markers for psychiatric illnesses include in vivo neuroanatomic and functional mag-
netic resonance imaging measurements and indices of neurocognitive abilities. However, neurocognitive and neuroimaging 
measures are by no means the only classes of endophenotypes that could be useful for identifying genes for mental illness. Given 
the advantages of endophenotype-based strategies for elucidating the genetic underpinnings of psychiatric disorders, it would 
seem prudent to develop a wide range of putative endophenotypes. In order for a measure to be considered a valid endophenotype, 
it must meet a number of criteria. Specifically, the trait must (1) have moderate to high heritability, (2) be associated with the 
illness, (3) be independent of clinical state, and (4) impairment must co-segregate with the illness within a family, with 
non-affected family members showing impairment relative to the general population. While each of these criteria is critical, the 
heritability and co-segregation requirements are really what differentiate an endophenotype from a simple biomarker. At this time, 
one requires an experimental design that includes families to demonstrate both heritability and co-segregation. The assertion that 
novel endophenotypes can not be fully established without family data does not preclude work in unrelated individuals, rather that 
unrelated samples will only be able to nominate potential candidate endophenotypes that subsequently need to be confirmed in 
family-based experiments.  
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Identification of the molecular mechanisms that increase 
risk for mental illnesses such as autism, bipolar disorder, 
major depression, and schizophrenia is of paramount im-
portance. Mental illnesses pose significant economic bur-
dens and are associated with substantial morbidity and 
mortality rates. However, with very few exceptions, their 
underlying pathologies are poorly understood. Identifying 
the specific genes that contribute to risk of these diseases 
will provide critical information about these illnesses that 
may lead to the development of novel diagnostic and thera-
peutic strategies. Although molecular genetic studies of 
mental diseases have made progress in recent years, bene-
fiting from a century of genetic epidemiology, the field lags 
behind those focused on other complex diseases in the iden-
tification of disease-related genes and subsequent biological 
inferences that result from discovering a causal component 
of the pathological chain. There are many reasons for this, 
including a historical overdependence on under-powered 
genetic study designs, as well as the dependence on noisy 
clinical phenotypes. However, a major reason for the slower 
pace of progress in the genetics of mental illness is the rela-
tive lack of emphasis on the collection and analysis of 
quantitative allied phenotypes or endophenotypes. Endo-
phenotypes are quantitative traits that are associated with 
disease liability, are heritable, can be measured in both af-
fected and unaffected individuals, and provide much greater 
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power to localize and identify disease-related genes than 
does affection status alone [1,2]. Using endophenotypic 
markers may be advantageous since they are thought to be 
less complex than their associated phenotype and thus may 
be more readily linked to a specific genetic locus [1,3], as 
they typically exhibit higher genetic signal-to-noise ratios 
than diagnosis [4]. In addition, endophenotypes for complex 
human psychiatric disorders could be potentially extended 
to animal models [5], advancing our understanding of the 
neurobiology of psychiatric disorders, and furthering the 
development of novel medications [6]. Using endopheno-
types to identify risk genes for mental illness is consistent 
with Strategic Objective 1 of the NIMH Strategic Plan: 
“Promote Discovery in the Brain and Behavioral Sciences 
to Fuel Research on the Causes of Mental Disorders” 
(http://www.nimh.nih.gov/about/strategic-planning-reports/i
ndex.shtml).  
Traditionally, endophenotypic markers for psychiatric 
illnesses include in vivo neuroanatomic and functional 
magnetic resonance imaging (MRI) measurements and in-
dices of neurocognitive abilities [7–9]. MRI-based measures 
of brain structure and function are highly heritable, as we 
have demonstrated in large extended pedigrees [10,11]. 
Neuroanatomic and neurophysiologic anomalies are found 
in most psychiatric illnesses, reflecting the underlying psy-
chopathology of these disorders [9,12]. Alterations in brain 
structure and function seen in individuals with psychiatric 
illnesses typically predate overt symptom expression [13–15]. 
In addition, many abnormalities associated with illness have 
been observed in individuals at risk for these same disorders 
[16–18]. Similar evidence for neurocognitive traits has ac-
cumulated, specifically that these traits are highly heritable 
[19], and are associated with neuropsychiatric illnesses and 
deficits in unaffected relatives [20,21]. Taken together, the-
se findings suggest that modern neuroimaging and neu-
rocognitive indices are extremely valuable endophenotypes 
for mental illnesses. However, neurocognitive and neu-
roimaging (and electrophysiological [22–24]) measures are 
by no means the only classes of endophenotypes that could 
be useful for identifying genes for mental illness. Indeed, 
other areas of perception or information processing (e.g. 
olfaction function [25]) or blood-based assays (e.g. [26]) 
could prove important measures of genetic liability for 
mental illness and help to delineate the genes and gene sys-
tems that predispose these illnesses. 
Given the advantages of endophenotype-based strategies 
for elucidating the genetic underpinnings of psychiatric dis-
orders, it would seem prudent to develop a wide range of 
putative endophenotypes. However, in order for a measure 
to be considered a valid endophenotype, it must meet a 
number of criteria. Specifically, the trait must (1) have 
moderate to high heritability, (2) be associated with the ill-
ness, (3) be independent of clinical state, and (4) impair-
ment must co-segregate with the illness within a family, 
with non-affected family members showing impairment 
relative to the general population [1,3,27,28]. While each of 
these criteria is critical, we note, importantly, that the herit-
ability and co-segregation requirements are really what dif-
ferentiate an endophenotype from a simple biomarker (any 
biological measure influenced by an illness) [5]. In general, 
endophenotypes can be considered that subset of bi-
omarkers influenced by genetic factors [5], with the implicit 
assumption that the same genetic factors that are influencing 
a particular endophenotype also confer risk for a particular 
illness (e.g. pleiotropy). At this time, one requires an ex-
perimental design that includes families (either twin pairs or 
pedigrees) to demonstrate both heritability and pleiotropy. 
The assertion that novel endophenotypes cannot be fully 
established without family data does not preclude work in 
unrelated individuals, rather that unrelated samples will 
only be able to nominate potential candidate endopheno-
types that subsequently need to be confirmed in fami-
ly-based experiments. However, the use of measures as al-
lied phenotypes or endophenotypes in large scale gene dis-
covery projects before the quantitative genetic properties of 
these indices is established seems premature and potentially 
quite wasteful. While endophenotypes offer a window into 
the pathophysiology of mental illness that could dramati-
cally improve our understanding of the biology of these 
debilitating illnesses, the naïve popularity of the term en-
dophenotype could undermine these efforts and derail the 
scientific community.  
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